US Bancorp’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-3,944
| Closed | -$59K | – | 4337 |
|
|
2022
Q3 | $59K | Buy |
3,944
+139
| +4% | +$1.62K | ﹤0.01% | 2444 |
|
|
2022
Q2 | $29K | Buy |
3,805
+120
| +3% | +$846 | ﹤0.01% | 2868 |
|
|
2022
Q1 | $34K | Buy |
3,685
+2,342
| +174% | +$18.1K | ﹤0.01% | 2820 |
|
|
2021
Q4 | $9K | Sell |
1,343
-807
| -38% | -$8.44K | ﹤0.01% | 3486 |
|
|
2021
Q3 | $25K | Buy |
2,150
+164
| +8% | +$2.4K | ﹤0.01% | 3025 |
|
|
2021
Q2 | $32K | Buy |
1,986
+51
| +3% | +$875 | ﹤0.01% | 2896 |
|
|
2021
Q1 | $35K | Sell |
1,935
-249
| -11% | -$4.3K | ﹤0.01% | 2763 |
|
|
2020
Q4 | $30K | Buy |
2,184
+874
| +67% | +$10.6K | ﹤0.01% | 2732 |
|
|
2020
Q3 | $16K | Buy |
1,310
+1,138
| +662% | +$13.9K | ﹤0.01% | 2918 |
|
|
2020
Q2 | $3K | Buy |
172
+54
| +46% | +$799 | ﹤0.01% | 3464 |
|
|
2020
Q1 | $2K | Sell |
118
-102
| -46% | -$1.94K | ﹤0.01% | 3508 |
|
|
2019
Q4 | $5K | Sell |
220
-61
| -22% | -$1.26K | ﹤0.01% | 3297 |
|
|
2019
Q3 | $5K | Buy |
281
+124
| +79% | +$2.84K | ﹤0.01% | 3262 |
|
|
2019
Q2 | $5K | Sell |
157
-413
| -72% | -$15.9K | ﹤0.01% | 3302 |
|
|
2019
Q1 | $27K | Buy |
570
+407
| +250% | +$17.9K | ﹤0.01% | 2749 |
|
|
2018
Q4 | $6K | Sell |
163
-937
| -85% | -$44K | ﹤0.01% | 3181 |
|
|
2018
Q3 | $67K | Buy |
1,100
+315
| +40% | +$20.2K | ﹤0.01% | 2418 |
|
|
2018
Q2 | $53K | Sell |
785
-147
| -16% | -$8.22K | ﹤0.01% | 2554 |
|
|
2018
Q1 | $50K | Buy |
932
+168
| +22% | +$9.4K | ﹤0.01% | 2627 |
|
|
2017
Q4 | $46K | Buy |
764
+273
| +56% | +$16.6K | ﹤0.01% | 2637 |
|
|
2017
Q3 | $24K | Buy |
+491
| New | +$26.8K | ﹤0.01% | 2829 |
|
|
2015
Q2 | – | Sell |
-4,430
| Closed | -$139K | – | 3667 |
|
|
2015
Q1 | $139K | Sell |
4,430
-310
| -7% | -$8.98K | ﹤0.01% | 1960 |
|
|
2014
Q4 | $138K | Buy |
+4,740
| New | +$120K | ﹤0.01% | 1950 |
|
US Bancorp's AERI Position: Q4 2022 in Review
US Bancorp sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 3,944 shares — an estimated $59K sold.
US Bancorp first reported a position in AERI in Q4 2014 and held it in 23 quarters. The position peaked at $139K in Q1 2015. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- US Bancorp reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- US Bancorp sold 3,944 Aerie Pharmaceuticals shares in Q4 2022, an estimated $59K.
- US Bancorp first reported a position in Aerie Pharmaceuticals in Q4 2014 and held it in 23 quarters.
- US Bancorp's Aerie Pharmaceuticals position peaked at $139K in Q1 2015.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on US Bancorp's 13F filing for Q4 2022, filed 13 Feb 2023.